Consolidative allogeneic HCT vs. a watch-and-wait approach for B-cell acute lymphoblastic leukemia patients with early loss of B-cell aplasia after CAR T-cell therapy.
Por:
Camarillas S, Alonso-Saladrigues A, Navarro V, Marsal-Ricoma J, Molinos Á, Delgado J, Herrero B, Rampotas A, Roddie C, Bücklein V, Subklewe M, Sánchez-Salinas M, González-Martínez B, Martin AÁ, Torrent A, Pérez-Martínez A, Iacoboni G, Rives-Solà S and Barba P
Ahead of Print:
29 sep 2026
Resumen:
Filiaciones:
Camarillas S:
Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain
Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain
Alonso-Saladrigues A:
Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain
Hospital Sant Joan de Déu Department of Pediatric Hematology and Oncology, Barcelona, Spain
Navarro V:
Oncology Data Science Group, Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Marsal-Ricoma J:
Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain
Hospital Sant Joan de Déu Department of Pediatric Hematology and Oncology, Barcelona, Spain
Molinos Á:
Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain
University Hospital Virgen del Rocío, Sevilla, Spain
Delgado J:
Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain
University Hospital Virgen del Rocío, Sevilla, Spain
Herrero B:
Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain
Niño Jesús University Children's Hospital, Madrid, Spain
Rampotas A:
University College of London Cancer Institute, London, UK
Roddie C:
University College of London Cancer Institute, London, UK
Bücklein V:
LMU University Hospital, München, Germany
Subklewe M:
LMU University Hospital, München, Germany
Sánchez-Salinas M:
Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain
Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain
Cellular Engineering and Hematologic Immunotherapy lab. Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain
González-Martínez B:
Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain
Department of Pediatric Hemato-Oncology, University Hospital La Paz, Madrid, Spain
Martin AÁ:
Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain
Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain
Torrent A:
Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain
Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, Spain
Pérez-Martínez A:
Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain
Department of Pediatric Hemato-Oncology, University Hospital La Paz, Madrid, Spain
IdiPAZ-CNIO Pediatric Onco-Hematology Clinical Research Unit, University Hospital La Paz, Madrid, Spain
Iacoboni G:
Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain
Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain
Cellular Engineering and Hematologic Immunotherapy lab. Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Rives-Solà S:
Hospital Sant Joan de Déu Department of Pediatric Hematology and Oncology, Barcelona, Spain
Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain
Barba P:
Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain
Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain
Cellular Engineering and Hematologic Immunotherapy lab. Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain
|